The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.
 
Dan-yun Ruan
No Relationships to Disclose
 
Fei Han
No Relationships to Disclose
 
Yujuan Zhou
No Relationships to Disclose
 
Fenghua Wang
No Relationships to Disclose
 
Lin-Quan Tang
No Relationships to Disclose
 
Zhiming Li
No Relationships to Disclose
 
Qiu-Yan Chen
No Relationships to Disclose
 
Chunyan Chen
No Relationships to Disclose
 
Jinguan Lin
No Relationships to Disclose
 
Fu-Rong Liu
Consulting or Advisory Role - KYM Biosciences
 
Feng Xiao
No Relationships to Disclose
 
Yingrui Shi
No Relationships to Disclose
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; CPPC; Hengrui Pharm; Hutchison MediPharma; Innovent Biologics; Junshi Pharmaceuticals; Keymed Biosience; Merck Serono; MSD; QiLu Pharmaceutical; Roche